Health and Healthcare
Amgen Nails Earnings, Guidance a Different Story
Published:
Last Updated:
Amgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings came in up 30% at $1.82 per share, and revenue was up 13% to $5.01 billion. Thomson Reuters had estimates of $1.68 in earnings per share and $4.82 billion in revenue. Product sales were up 11% in the quarter.
Guidance for all of 2014 was put at $7.90 to $8.20 in earnings per share and $19.2 to $19.6 billion in revenue. Thomson Reuters had estimates of $8.18 in earnings per share and $19.58 billion in revenue.
Amgen now has 10 drug development programs with registration-enabling data expected by 2016. It also claims to have six biosimilars in development and has expanded presence in more than 75 countries.
Neulasta and Neupogen sales combined were up 8% for the quarter, and some select product sales growth was as follows: Enbrel up 3% (driven by price), Aranesp dropped 4% on lower unit demand, Sensipar/Mimpara sales increased 20% based on unit demand and price.
Amgen shares closed up 1.8% at $120.70, against a 52-week range of $39.24 to $84.40. The after-hours reaction had shares down only a few pennies initially.
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.